

CITATION REPORT

List of articles citing

Low blood concentration of hydroxychloroquine in patients with refractory cutaneous lupus erythematosus: a French multicenter prospective study

DOI: 10.1001/archdermatol.2011.2558
Archives of Dermatology, 2012, 148, 479-84.

Source: <https://exaly.com/paper-pdf/52687113/citation-report.pdf>

Version: 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
132	[What's new in internal medicine?]. 2012 , 139 Suppl 5, S194-201		
131	A rapid and reliable method for the quantitation of hydroxychloroquine in serum using turbulent flow liquid chromatography-tandem mass spectrometry. 2013 , 421, 79-84		33
130	Cutaneous lupus erythematosus: diagnosis and treatment. 2013 , 27, 391-404		152
129	Adherence to treatment in systemic lupus erythematosus patients. 2013 , 27, 329-40		106
128	Recent progress in conventional and biologic therapy for systemic lupus erythematosus. 2013 , 72 Suppl 2, ii66-8		7
127	Update on Epidemiology and Clinical Assessment Tools of Cutaneous Lupus Erythematosus and Dermatomyositis. 2013 , 2, 48-57		
126	Antipalúdicos de síntesis en dermatología. <i>EMC - Dermatología</i> , 2013 , 47, 1-8	0.1	
125	Multifaceted effects of hydroxychloroquine in human disease. 2013 , 43, 264-72		88
124	Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study). 2013 , 72, 1786-92		126
123	Update on pathogenesis and treatment of CLE. <i>Current Opinion in Rheumatology</i> , 2013 , 25, 584-90	5.3	15
122	A cross-sectional study of hydroxychloroquine concentrations and effects in people with systemic lupus erythematosus. 2013 , 43, 547-53		15
121	Antipalúdicos de síntesis en dermatología. 2013 , 8, 1-7		
120	14th International Congress on Antiphospholipid Antibodies: task force report on antiphospholipid syndrome treatment trends. 2014 , 13, 685-96		248
119	Therapeutic drug monitoring in rheumatic diseases: utile or futile?. 2014 , 53, 988-97		16
118	Design and evaluation of a highly sensitive nanostructure-based surface modification of glassy carbon electrode for electrochemical studies of hydroxychloroquine in the presence of acetaminophen. 2014 , 123, 648-56		21
117	The immunopathology of cutaneous lupus erythematosus. <i>Rheumatic Disease Clinics of North America</i> , 2014 , 40, 455-74, viii	2.4	20
116	Development, validation and clinical application of a LC-MS/MS method for the simultaneous quantification of hydroxychloroquine and its active metabolites in human whole blood. 2014 , 100, 131-137		23

115	Hydroxychloroquine: a multifaceted treatment in lupus. 2014 , 43, e167-80		101
114	Determinants of hydroxychloroquine blood concentration variations in systemic lupus erythematosus. 2015 , 67, 2176-84		87
113	Adherence to Oral and Topical Medications in Cutaneous Lupus Erythematosus is not Well Characterized. 2015 , 5, 91-105		13
112	Manifestaciones cutáneas del lupus eritematoso. <i>EMC - Dermatología</i> , 2015 , 49, 1-14	0.1	0
111	A Critical Review of the Effects of Hydroxychloroquine and Chloroquine on the Eye. 2015 , 49, 317-26		77
110	From pathogenesis, epidemiology, and genetics to definitions, diagnosis, and treatments of cutaneous lupus erythematosus and dermatomyositis: a report from the 3rd International Conference on Cutaneous Lupus Erythematosus (ICCLE) 2013. 2015 , 135, 7-12		26
109	Multiwall carbon nanotube-modified electrode as a nanosensor for electrochemical studies and stripping voltammetric determination of an antimalarial drug. 2015 , 5, 14407-14415		16
108	Influence of smoking on the efficacy of antimalarials in cutaneous lupus: a meta-analysis of the literature. <i>Journal of the American Academy of Dermatology</i> , 2015 , 72, 634-9	4.5	69
107	Mepacrine in Recalcitrant Cutaneous Lupus Erythematosus: Old-fashioned or Still Useful?. 2015 , 95, 596-9		9
106	Hydroxychloroquine Blood Levels in Systemic Lupus Erythematosus: Clarifying Dosing Controversies and Improving Adherence. 2015 , 42, 2092-7		98
105	Hydroxychloroquine reduces microglial activity and attenuates experimental autoimmune encephalomyelitis. 2015 , 358, 131-7		33
104	Routine Hydroxychloroquine Blood Concentration Measurement in Systemic Lupus Erythematosus Reaches Adulthood. 2015 , 42, 1997-9		11
103	Immunomodulators in SLE: Clinical evidence and immunologic actions. 2016 , 74, 73-84		54
102	Hydroxychloroquine Serum Concentrations and Flares of Systemic Lupus Erythematosus: A Longitudinal Cohort Analysis. 2016 , 68, 1295-302		58
101	It hasn't gone away: the problem of glucocorticoid use in lupus remains. 2017 , 56, i114-i122		29
100	Connective Tissue Disease. 2016 ,		1
99	Conventional Treatment of Systemic Lupus Erythematosus. 2016 , 213-238		
98	Mycophenolate Mofetil in Refractory Cutaneous Lupus Erythematosus: No Definitive Evidence. 2016 , 43, 1766		1

97	Reply. 2016 , 170, 239-240		
96	Reply. 2016 , 170, 240-241		
95	The Prevalence of Hydroxychloroquine Retinopathy and Toxic Dosing, and the Role of the Ophthalmologist in Reducing Both. 2016 , 170, 240		7
94	Retinopathy in the Era of Routine Hydroxychloroquine Monitoring. 2016 , 43, 1254		1
93	New Perspectives in Rheumatology: Avoiding Antimalarial Toxicity. 2016 , 68, 1805-9		2
92	Population Pharmacokinetics of Hydroxychloroquine in Japanese Patients With Cutaneous or Systemic Lupus Erythematosus. 2016 , 38, 259-67		39
91	Therapeutic options for cutaneous lupus erythematosus: recent advances and future prospects. 2016 , 12, 1109-21		10
90	Association of Polymorphisms of Cytochrome P450 2D6 With Blood Hydroxychloroquine Levels in Patients With Systemic Lupus Erythematosus. 2016 , 68, 184-90		81
89	Cutaneous Lupus Erythematosus: An Update on Pathogenesis, Diagnosis and Treatment. 2016 , 17, 135-46		62
88	Quality of life in systemic lupus erythematosus: description in a cohort of French patients and association with blood hydroxychloroquine levels. <i>Lupus</i> , 2016 , 25, 735-40	2.6	18
87	The effect of increasing the dose of hydroxychloroquine (HCQ) in patients with refractory cutaneous lupus erythematosus (CLE): An open-label prospective pilot study. <i>Journal of the American Academy of Dermatology</i> , 2016 , 74, 693-9.e3	4.5	44
86	Adherence in dermatology. 2017 , 28, 94-103		25
85	Efficacy and comparison of antimalarials in cutaneous lupus erythematosus subtypes: a systematic review and meta-analysis. 2017 , 177, 188-196		45
84	Longterm Hydroxychloroquine Therapy and Low-dose Aspirin May Have an Additive Effectiveness in the Primary Prevention of Cardiovascular Events in Patients with Systemic Lupus Erythematosus. 2017 , 44, 1032-1038		58
83	Updated recommendations on the use of hydroxychloroquine in dermatologic practice. <i>Journal of the American Academy of Dermatology</i> , 2017 , 76, 1176-1182	4.5	29
82	Hydroxychloroquine in systemic lupus erythematosus (SLE). 2017 , 16, 411-419		153
81	[Blood concentration of hydroxychloroquine in systemic lupus erythematosus care: Usefulness and limits]. <i>Revue De Medecine Interne</i> , 2017 , 38, 77-80	0.1	1
80	Therapeutic monitoring of the immuno-modulating drugs in systemic lupus erythematosus. 2017 , 13, 35-41		21

79	Hydroxychloroquine blood concentration in lupus nephritis: a determinant of disease outcome?. 2018 , 33, 1604-1610		18
78	Cutaneous lupus erythematosus: Reflecting on practice-changing observations over the past 50 years. 2018 , 36, 442-449		6
77	The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults. 2018 , 57, e1-e45		150
76	Sharp decline in hydroxychloroquine dosing-analysis of 17,797 initiators from 2007 to 2016. 2018 , 37, 1853-1859		6
75	Adherence to treatment in patients with systemic lupus erythematosus. 2018 , 150, 8-15		8
74	Changing antimalarial agents after inefficacy or intolerance in patients with cutaneous lupus erythematosus: A multicenter observational study. <i>Journal of the American Academy of Dermatology</i> , 2018 , 78, 107-114.e1	4.5	24
73	Steady-state pharmacokinetics of hydroxychloroquine in patients with cutaneous lupus erythematosus. <i>Lupus</i> , 2018 , 27, 847-852	2.6	24
72	A Prospective International Study on Adherence to Treatment in 305 Patients With Flaring SLE: Assessment by Drug Levels and Self-Administered Questionnaires. 2018 , 103, 1074-1082		24
71	Adherence to treatment in patients with systemic lupus erythematosus. 2018 , 150, 8-15		1
70	Effect of in utero hydroxychloroquine exposure on the development of cutaneous neonatal lupus erythematosus. 2018 , 77, 1742-1749		28
69	A Prospective International Study on Adherence to Treatment in 305 Patients With Flaring SLE: Assessment by Drug Levels and Self-Administered Questionnaires. 2019 , 106, 374-382		20
68	Breast milk concentration of hydroxychloroquine in Chinese lactating women with connective tissue diseases. 2019 , 75, 1547-1553		7
67	Are the Current Recommendations for Chloroquine and Hydroxychloroquine Screening Appropriate?. <i>Rheumatic Disease Clinics of North America</i> , 2019 , 45, 359-367	2.4	6
66	Impact of tobacco smoking upon disease risk, activity and therapeutic response in systemic lupus erythematosus: A systematic review and meta-analysis. 2019 , 18, 102393		19
65	Current Concepts and Future Approaches in the Treatment of Cutaneous Lupus Erythematosus: A Comprehensive Review. 2019 , 79, 1199-1215		14
64	Association between hydroxychloroquine levels and disease activity in a predominantly Hispanic systemic lupus erythematosus cohort. <i>Lupus</i> , 2019 , 28, 862-867	2.6	14
63	A review of the evidence and cost of therapies for cutaneous lupus erythematosus. <i>Lupus</i> , 2019 , 28, 799-805		1
62	Analyses of Skin and Peripheral Blood Transcriptional Data in Cutaneous Lupus Reveals CCR2-A Novel Potential Therapeutic Target. 2019 , 10, 640		4

61	Refractory lupus nephritis: When, why and how to treat. 2019 , 18, 510-518		24
60	Effect of Hydroxychloroquine and Anti-BDCA2 mAb Treatment on pDC IFN γ Production From Patients Affected With Cutaneous Lupus Erythematosus. 2019 , 10, 275		19
59	Pathogenesis of Cutaneous Lupus. 2019 , 305-316.e4		1
58	Systemic Glucocorticoid Therapy for SLE. 2019 , 661-672		
57	Management of Cutaneous Lupus Erythematosus. 2019 , 719-726		
56	Antimalarial resistance in lupus: a lesser-explored terrain. <i>Lupus</i> , 2019 , 28, 145-146	2.6	
55	Connective Tissue Disease: Current Concepts. 2019 , 37, 37-48		4
54	Hydroxychloroquine Levels throughout Pregnancies Complicated by Rheumatic Disease: Implications for Maternal and Neonatal Outcomes. 2019 , 46, 57-63		19
53	Patients opinion and adherence to antimalarials in lupus erythematosus and rheumatoid arthritis treatment. 2020 , 31, 264-269		1
52	An update on the use of hydroxychloroquine in cutaneous lupus erythematosus: A systematic review. <i>Journal of the American Academy of Dermatology</i> , 2020 , 82, 709-722	4.5	12
51	Management of cutaneous manifestations of lupus erythematosus: A systematic review. 2020 , 50, 95-127		18
50	Hydroxychloroquine is a novel therapeutic approach for rosacea. 2020 , 79, 106178		14
49	Hydroxychloroquine levels in patients with systemic lupus erythematosus: whole blood is preferable but serum levels also detect non-adherence. 2020 , 22, 223		5
48	Interaction of Hydroxychloroquine with Pharmacokinetically Important Drug Transporters. 2020 , 12,		4
47	Degradation of hydroxychloroquine by electrochemical advanced oxidation processes. 2020 , 402, 126279		34
46	Current Trends in Analytical Methods for the Determination of Hydroxychloroquine and Its Application as Treatment for COVID-19. 2020 , 5, 14602-14612		4
45	Manifestaciones cutáneas del lupus eritematoso. <i>EMC - Dermatología</i> , 2020 , 54, 1-17		0.1
44	Adherence to hydroxychloroquine in patients with systemic lupus: Contrasting results and weak correlation between assessment tools. 2020 , 87, 603-610		3

43	Understanding the dynamics of hydroxychloroquine blood levels in lupus nephritis. <i>Lupus</i> , 2020 , 29, 560-568	9
42	Hydroxychloroquine reduces the risk of covid-19 in patients with rheumatic diseases: myth or reality?. 2021 , 80, e6	2
41	Clinical Significance of Monitoring Hydroxychloroquine Levels in Patients With Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis. 2021 , 73, 707-716	9
40	Antimalarial Agents. 2021 , 234-244.e4	1
39	Prescription strategy of antimalarials in cutaneous and systemic lupus erythematosus: an international survey. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021 , 13, 1759720X211002595	3.8 2
38	Efficacy and safety of hydroxychloroquine for treatment of patients with rosacea: A multicenter, randomized, double-blind, double-dummy, pilot study. <i>Journal of the American Academy of Dermatology</i> , 2021 , 84, 543-545	4.5 6
37	One-year prospective nerve conduction study of thalidomide neuropathy in lupus erythematosus: Incidence, coasting effect and drug plasma levels. <i>Lupus</i> , 2021 , 30, 956-964	2.6 1
36	Observance du traitement par hydroxychloroquine dans le lupus systématique : résultats contrastés et faible corrélation entre les outils d'évaluation. 2021 , 88, 369-376	
35	Quantification of Hydroxychloroquine in Blood Using Turbulent Flow Liquid Chromatography-Tandem Mass Spectrometry (TFLC-MS/MS). 2016 , 1383, 177-84	3
34	Dermatologists' Adherence to the Latest Recommendations for Screening of Hydroxychloroquine Retinopathy in Saudi Arabia: Cross-Sectional Study. 2019 , 8, e15218	2
33	Expanding horizons for clinical applications of chloroquine, hydroxychloroquine, and related structural analogues. 2019 , 8,	25
32	Comment je traite une atteinte cutanée lupique réfractaire aux antipaludéens de synthèse ?. 2013 , 241-245	
31	Subacute Cutaneous Lupus Erythematosus in Older Man: Case Report. <i>Journal of Biosciences and Medicines</i> , 2017 , 05, 25-33	0.2
30	Antipalúdicos de síntesis en dermatología. <i>EMC - Dermatología</i> , 2020 , 54, 1-11	0.1
29	Precision Medicine: Towards Individualized Dosing in Pediatric Rheumatology. <i>Rheumatic Disease Clinics of North America</i> , 2022 , 48, 305-330	2.4 2
28	Prenatal predisposing factors associated with neonatal lupus erythematosus.. <i>Lupus</i> , 2022 , 9612033211066455	
27	LC-MS/MS Method for Determination of Hydroxychloroquine and Metabolites: Application in a Pharmacokinetic Study.. <i>Journal of Analytical Methods in Chemistry</i> , 2022 , 2022, 6058445	2 0
26	Cutaneous Lupus. 2022 , 25-52	

25	Correlation of whole blood hydroxychloroquine concentration with cutaneous lupus erythematosus and factors associated with it: First multicenter, cross-sectional analysis in Malaysia.. <i>Journal of Dermatology</i> , 2022 ,	1.6	
24	Hydroxychloroquine in systemic lupus erythematosus: overview of current knowledge.. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2022 , 14, 1759720X211073001	3.8	5
23	Prevalence and factors associated with long-term remission in cutaneous lupus: a longitudinal cohort study of 141 cases.. <i>Journal of the American Academy of Dermatology</i> , 2022 ,	4.5	0
22	Advances in the clinical use of hydroxychloroquine levels.. <i>Current Opinion in Rheumatology</i> , 2022 , 34, 151-157	5.3	0
21	Image_1.TIF. 2019 ,		
20	Image_2.TIF. 2019 ,		
19	Image_3.TIF. 2019 ,		
18	Image_4.TIF. 2019 ,		
17	Image_5.TIF. 2019 ,		
16	Table_1.xlsx. 2019 ,		
15	Data_Sheet_1.PDF. 2019 ,		
14	Data_Sheet_2.PDF. 2019 ,		
13	Data_Sheet_3.PDF. 2019 ,		
12	Data_Sheet_4.PDF. 2019 ,		
11	Data_Sheet_5.PDF. 2019 ,		
10	Data_Sheet_6.PDF. 2019 ,		
9	Data_Sheet_7.PDF. 2019 ,		
8	Data_Sheet_8.PDF. 2019 ,		

7	Image_1.TIF. 2019 ,		
6	Drug monitoring in systemic lupus erythematosus.. <i>Current Opinion in Pharmacology</i> , 2022 , 64, 102225	5.1	
5	Antimalarial agents. 2013 , 241-251.e3		3
4	Intérêt des dosages pharmacologiques d'immunosuppresseurs et immunomodulateurs dans la prise en charge des maladies autoimmunes. <i>Revue De Medecine Interne</i> , 2022 ,	0.1	1
3	Impact of an Electronic Decision Support Tool to Improve Ophthalmic Safety in Hydroxychloroquine Prescribing Practices. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2022 , 53, 310-316	1.4	
2	An update on the management of refractory cutaneous lupus erythematosus. 9,		1
1	Rapid Onset and Resolution of Hydroxychloroquine Cardiomyopathy: A Case Report. 2022 , 2022, 1-4		0